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A three-in-one-bullet for oesophageal cancer: Replication fork 
collapse, spindle attachment failure and enhanced radiosensitivity 
generated by a ruthenium(II) metallo-intercalator† 
Martin R. Gill,*a Paul J. Jarman,b,c Swagata Halder,a Michael G. Walker,b Hiwa K. Saeed,b Jim A. 
Thomas,b Carl Smythe,c Kristijan Ramadan,a Katherine A. Vallis*a 
Substitutionally inert ruthenium(II) polypyridyl complexes have been developed as DNA intercalating agents yet cellular 
DNA damage responses to this binding modality are largely unexplored. Here, we show the nuclear-targeting complex 
[Ru(phen)2(tpphz)]
2+ (phen = 1,10-phenanthroline, tpphz = tetrapyridophenazine) generates rapid and pronounced stalling 
of replication fork progression in p53-deficient human oesophageal cancer cells. In response, replication stress and 
double-strand break (DSB) DNA damage response (DDR) pathways are activated and cell proliferation is inhibited by 
growth arrest. Moreover, mitotic progression is compromised by [Ru(phen)2(tpphz)]
2+, where the generation of metaphase 
chromosome spindle attachment failure results in spindle assembly checkpoint (SAC) activation. This dual mechanism of 
action results in preferential growth inhibition of rapidly-proliferating oesophageal cancer cells with elevated mitotic 
indices. In addition to these single-agent effects, [Ru(phen)2(tpphz)]
2+ functions as a radiosensitizer with efficiency 
comparable to cisplatin, which occurs through a synergistic enhancement of DNA damage. These results establish that 
DNA replication is the target for [Ru(phen)2(tpphz)]
2+ and provide the first experimental evidence that ruthenium-based 
intercalation targets multiple genome integrity pathways in cancer cells, thereby achieving enhanced selectivity compared 
to existing DNA-damaging agents such as cisplatin. 
Introduction  
Small molecules that interfere with DNA replication are widely-
used anti-cancer drugs and are often employed in combination 
therapy alongside ionising radiation (IR) to treat cancer.
1, 2
 One 
example of a clinical radiosensitizer is the platinum drug 
cisplatin, which generates both inter and intra-strand Pt-DNA 
cross-links and double-strand breaks (DSBs) that slow cell-cycle 
progression through S-phase, exacerbating IR-induced DNA 
damage.
3, 4
 Although cisplatin-based chemoradiotherapy is 
highly effective in many cases, oesophageal cancers are 
marked by poor 5-year survival rates, typically <20%.
5
 Cisplatin 
is associated with nephrotoxicity which limits dose escalation 
and attempts to improve the outcome of patients with 
oesophageal cancer using alternative DNA-damaging 
chemotherapy such as doxorubicin have been unsuccessful.
6
 
Application of these potent cytotoxic agents has also been 
hampered by the fact that the majority (77%) of oesophageal 
cancers lack p53 function7 and therefore possess a reduced 
capacity to activate apoptotic pathways in response to 
significant DNA damage.
8
 Thus, less toxic compounds that 
operate by alternative mechanisms of action and can also 
function as radiosensitizers are required.  
As typified by [Ru(bpy)2(dppz)]
2+
 (bpy = 2,2-bipyridine, dppz = 
dipyridophenazine),
9
 inert ruthenium(II) polypyridyl complexes 
(RPCs) that interact with DNA solely via intercalation have 
been developed as site- and structure-specific luminescent 
DNA binding agents.
9, 10
 Recent X-ray crystal structures have 
provided molecular insight into RPC metallo-intercalation in 
unprecedented detail.
11-16
 This includes evidence that 
[Ru(phen)2(dppz)]
2+
 (phen = 1,10-phenanthroline) adopts 
multiple intercalative geometries
12
 and Ru(dppz) semi-
intercalation induces marked kinking of duplex DNA;
11
 a 
structural distortion similar to that observed following 
platination.
17
 Based on these studies with isolated DNA, the 
cellular uptake and anti-cancer properties of RPCs have 
become of increasing interest.
18-20
 However, despite the large 
number of DNA-interactive RPCs that have now been screened 
for anti-cancer activity,
21
 few have unequivocally been shown 
to have genomic DNA as their pharmacological target.
22-24
 As a 
result, cellular DNA damage responses to lesions generated by 
RPC mono-intercalation are completely unknown; a 
considerable barrier to therapeutic development of this class 
of DNA-binding agent. Moreover, while RPCs have generated 
much interest as photosensitizers for photodynamic therapy 
(PDT),
25-27
 studies of RPCs in combination with IR have been 
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rare.
23, 28, 29
 This is surprising as radiotherapy is a mainstay of 
cancer medicine: high-energy X-rays or targeted radionuclide 
therapeutics have a far greater depth of penetration in tissue 
than visible light and radiotherapy is therefore capable of 
targeting a wider range of cancers.
2,30
  
[Ru(phen)2(tpphz)]
2+
 (tpphz = tetrapyrido[3,2-a:2′,3′-c:3′′,2′′-
h:2′′′,3′′′-j]phenazine), Ru1 (Fig. 1a), is a water-soluble 
hydrophilic mono-intercalator (log P = -1.24, DNA Kb = 3x10
5
 
M
-1
) that shows in vitro anti-cancer activity
31
 and toxicity has 
been established in murine models.
32
 Here, we present a 
detailed characterisation of the cellular response to DNA 
damage generated by Ru1 in p53-deficient oesophageal cancer 
cells and explore the complex in combination with IR. 
 
 
Fig. 1 (a) Structures of Ru1 and dppz. Ru1 was used as the chloride salt and as a mixture 
of Λ and Δ enantiomers. (b) Representative images of DNA replication fibres in OE21 
oesophageal cancer cells. CldU (first pulse, 30 mins) incorporation is shown in red, 
incorporated IdU (second pulse, 30 mins) in green. The second nucleotide (IdU) was 
either mock-treated or incubated in the presence of Ru1 or dppz to determine impact 
on DNA replication fork progression. Scale bar = 10 µm. (c) Quantification of IdU-
labelled tract length in the presence of Ru1 (21 µM) or dppz (7 µM). Tract length was 
determined for >100 forks per condition. Whisker box plots show mean values and data 
within the 10–90 percentile. (d) Quantification of completely stalled forks (i.e. CldU 
tract only) for Ru1 or dppz treatment as in (b). Fork stalling was quantified for >300 
forks per condition and experiment. The experiment was repeated three times. Data 
were analysed using unpaired two-tailed t test (*P < 0.1, **P < 0.01, ***P < 0.005). 
Results and Discussion 
Nuclear localisation of Ru1  
Previous confocal laser scanning microscopy (CLSM) and 
transmission electron microscopy (TEM) studies indicated that 
Ru1 targets nuclear DNA.
31
 ICP-MS (inductively coupled plasma 
mass spectrometry) analysis confirmed high (>70%) cellular 
ruthenium content in isolated nuclear fractions of Ru1-treated 
oesophageal cancer cells (Fig. S1 in the ESI†) while visualisaVon 
of intracellular MLCT (metal to ligand charge-transfer) 
emission of Ru1 in OE21 oesophageal squamous cell 
carcinoma (ESCC) cells showed strong overlap with the DNA 
dye DAPI (Fig. S2†). In comparison, OE21 cells treated with 
[Ru(phen)2(dppz)]
2+
 (log P = -1.48
17
) possessed a 13-fold lower 
average cellular Ru content and a 28-fold reduction in nuclear 
Ru content than cells treated with Ru1 (Fig. S1a†). In addiVon 
to this, minimal nuclear MLCT emission in [Ru(phen)2(dppz)]
2+
-
treated cells was evident by CLSM (Fig. S2†). These results 
indicate substantially greater cellular uptake and enhanced 
nuclear targeting are demonstrated by Ru1 over 
[Ru(phen)2(dppz)]
2+
. 
 
Ru1 stalls replication fork progression 
On the basis of our recent discovery that the multi-intercalator 
[Ru(dppz)2(PIP)]
2+
 (PIP = 2-(phenyl)imidazo[4,5-
f][1,10]phenanthroline) is able to stall replication forks,
23
 the 
ability of Ru1 to similarly affect DNA replication was examined 
by DNA fibre assay. By sequential incorporation of 
halogenated nucleotides and immunofluorescence staining, 
this technique allows visualisation of the progression of 
individual replicating DNA strands.
33, 34
 Accordingly, OE21 cells 
were pulse-labelled with the thymidine analogue CIdU for 30 
min before treatment with Ru1 and concomitant labelling with 
a second thymidine analogue (IdU) for an additional 30 min, 
thereby allowing examination of the direct impact of Ru1 upon 
replication fork progression (Fig. 1b). Strikingly, the addition of 
21 µM Ru1 (the 24 h IC50 concentration, Table 1) in this 
manner resulted in a large decrease in median IdU tract length 
in DNA fibres, indicating extensive replication fork stalling 
generated due to the inclusion of the complex (Fig. 1c). This 
was accompanied by a 1.7-fold increase in completely 
stalled/terminated replication forks (CldU tract only – Fig. 1d). 
This marked impact on replication fork progression indicates 
pronounced and rapid DNA replication inhibition is generated 
directly by the addition of Ru1; an unprecedented result for a 
substitutionally inert metal complex that binds DNA solely by 
mono-intercalation. 
 
DNA damage response (DDR) activation by Ru1 
To examine DNA damage response (DDR) cell signalling 
activation in response to lesions generated by Ru1, we carried 
out western blot analyses of protein extracts of OE21 cells 
using antibodies against the phosphorylated (activated) forms 
of several DDR signalling proteins. In Ru1-treated cells, an 
increased level of Chk1 phosphorylation at Ser345 and 
phospho-ATR (at Ser428) (ATR = ataxia telangiectasia and 
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Rad3-related protein) at 3 h onwards indicated activation of 
ATR/Chk1 signalling (Fig. 2a), in agreement with generation of 
replication stress as a result of stalled replication forks.
8
 An 
increased level of phospho-Chk2 (Thr68) and γH2AX (Histone 
H2AX phosphorylated at Ser139), both of which are generated 
following DNA double-strand damage,
8
 was also apparent, the 
level of each increased with Ru1 exposure time (Fig. 2a). 
Comparable temporal DDR activation induced by Ru1 was 
observed in wild type p53-containing MCF7 breast cancer cells, 
showing that DDR activation occurs independently of p53 
status (Fig. S3†). These results show Ru1 induces both 
replication stress and double-strand break (DSB) DDR pathway 
activation; a hallmark of replication fork collapse.35 
 
Fig. 2 (a) DNA damage response (DDR) activation by Ru1. Whole-cell extracts of OE21 
cells treated with Ru1 (20 μM) for 1, 3, 8 or 24 h were immunoblotted for activated 
(phosphorylated, p) p-Chk1 (Ser345), p-Chk2 (Thr68), p-ATR (Ser428) or γH2AX (pH2AX 
at Ser139), as indicated. Total Chk1 and Chk2 protein levels independent of 
phosphorylation status are shown. α-tubulin or β-actin were used as loading controls. 
(b) Relative expression of pChk1 and pChk2 in OE21 cells treated with equipotent (IC50) 
concentrations of cisplatin (23 μM), dppz (7 μM) or Ru1 (21 μM) for 3 h, as determined 
by immunoblotting and quantified by densitometry (bottom panels). Phosphorylated 
protein levels relative to total protein and normalised to control are presented. 
γH2AX/β-actin ratio also provided. (c) Impact of Ru1, dppz, [Ru(phen)2(dppz)]
2+ or 
cisplatin on viability of OE21 cells, as determined by MTT assay (24 h incubation time). 
Mean of quadruplicates +/- S.D. and representative of two independent experiments. 
(d) Immunoblotting of γH2AX levels in OE21 cells after 24 h treatment with cisplatin 
(Cis), Ru1 or dppz (IC50 and IC70 concentrations). [Ru(phen)2(dppz)]
2+ treatment also 
included. Whole-cell extracts were immunoblotted for. β-actin was used as a loading 
control. * 0.25% DMSO.  
 
 
Impact of dppz on replication fork progression  
Although X-ray crystal structures have confirmed that DNA 
intercalation of RPCs is achieved primarily through the 
insertion of extended coordinated polypyridyl ligand(s) 
between base pairs,
11-16
 it is unknown whether this effect 
drives bioactivity. As poor solubility prevented the use of free 
tpphz, the cellular response to free (non-coordinated) dppz 
(Fig. 1a) – a close structural analogue of tpphz and the 
prototypical polypyridyl intercalating ligand – was also 
examined. As seen in Figs 1b-d, replication fork progression in 
OE21 cells was impaired after the addition of 7 µM dppz, as 
indicated by a substantial decrease in IdU tract length and 
large (three-fold) increase in levels of stalled forks compared 
to mock-treated. The similarity of the impact on replication 
fork progression for dppz and Ru1 is consistent with the notion 
that polypyridyl ligand intercalation is responsible for 
replication inhibition. However, approximately two-fold 
greater levels of stalled forks are generated by dppz than Ru1, 
indicating a more potent replication block generated by the 
organic ligand (Fig. 1d). Examining DDR activation due to dppz 
treatment, high pChk1 levels and decreased levels of the DSB 
damage marker γH2AX and pChk2 activation in comparison to 
Ru1 treatment were apparent, indicating reduced DSB damage 
pathway activation by dppz (Figs 2b,d).  
In comparison to Ru1 and dppz, [Ru(phen)2(dppz)]
2+ 
demonstrated substantially reduced impact on cell 
proliferation along with no evidence of DDR activation (Figs 
2c,d). This may be explained by the reduced cellular uptake of 
[Ru(phen)2(dppz)]
2+ compared to Ru1 (vide supra). The low 
bioactivity and poor nuclear targeting of [Ru(phen)2(dppz)]
2+ 
are in agreement with other studies.18, 32 
 
Global response to Ru1-induced DNA damage 
Depending upon the precise lesion generated, the cellular 
response to unrepaired DNA damage is typically either cell-
cycle arrest or cell death.36 High levels of γH2AX foci are 
retained for a substantial time after Ru1 treatment of OE21 
cells (Figs 3a,b), indicating prolonged DDR activation generated 
by the complex and the persistence of unrepaired DNA. 
Examining impact on cell-cycle progression, treatment of 
cycling OE21 cells with Ru1 induced a two-fold increase in 
G2/M phase cells compared to control (Fig. 3c). A distinct cell-
cycle response was induced in response to dppz where instead 
cells accumulated in G1 or early S phase (Fig. 3c). In contrast to 
cisplatin treatment, limited evidence of Annexin-V-positive 
cells, no observable karyorrhexis and reduced cleaved caspase 
3 expression was observed in OE21 cells treated with Ru1 (Figs 
3d, S4† and S5†), indicaVng low levels of apoptosis. Despite 
this, a loss of proliferative capacity as a result of Ru1 
treatment was shown by clonogenic survival assay (Fig. 3e). 
Furthermore, numerous growth-arrested Ru1-treated OE21 
cells appeared “ﬂaZened” with enlarged nuclei (Fig. S5†), a 
characteristic phenotype of senescence.
37
 These results are 
therefore consistent with permanent growth arrest being the 
primary response to Ru1-generated DNA damage in OE21 
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cells; although Trypan Blue staining indicates ~20% necrotic 
cell death to accompany this outcome (Fig. S5a†). 
 
Fig. 3  (a) Representative CLSM images of OE21 cells treated with Ru1 (20 µM, 24 h) 
visualised at 0, 1, 6 and 24 h after complex removal. Immunofluorescence staining with 
anti-γH2AX antibody (white) provides visualisation of DSB damage. DNA (DAPI) staining 
included for reference. Scale bars = 20 µm. (b) Quantification of γH2AX foci/nucleus for 
OE21 cells treated as in (a). Data mean +/- S.D. of four or five micrographs where a 
minimum of 20 nuclei were counted per image. (c) Impact of Ru1 (20 μM, 24 h) or dppz 
(7 µM, 24 h) on cell-cycle distribution of OE21 cells, as determined by flow cytometric 
analysis of DNA content. DNA content in Ru1-treated cells was quantified using the 
MLCT emission of Ru1 (see Experimental section). Data are mean of three independent 
experiments +/− S.D. (d) AnnexinV staining of OE21 cells treated with cisplatin (23 µM), 
Ru1 (21 µM) or dppz (7 µM) for 24 h, as determined by flow cytometry. Average of two 
independent experiments +/- S.D. (e) Clonogenic survival of OE21 cells treated with 
Ru1, cisplatin or dppz (24 h incubation time). Average of triplicates +/- S.D. 
 
The targeting of genomic DNA without generating high levels 
of apoptosis by Ru1 is a distinct cellular response compared to 
cisplatin. While at first this appears surprising, Ru1 and 
cisplatin possess different DNA binding modalities (cisplatin 
forms covalent Pt-DNA adducts while Ru1 binds non-covalently 
via intercalation) and growth arrest in response to DNA-
damage is common, particularly in cells that lack functional 
p53 and thus possess a reduced capacity to activate 
apoptosis.
36
 It is also evident that Ru1 demonstrates a 
different mechanism of action compared to structurally-
related hydrophobic mitochondrial-targeting RPCs, which 
induce reactive oxygen species (ROS)-mediated apoptosis.
38-40
 
As the hydrophilic Ru1 instead targets nuclear DNA, this 
illustrates the role of organelle targeting in determining RPC 
bioactivity. 
The differential DDR activation and cell-cycle deregulation 
exhibited by Ru1 and dppz are also noteworthy. This may be 
rationalised by the greater levels of stalled forks generated by 
dppz resulting in a potent G1-S block. For Ru1, fork collapse 
instead results in slowed progression through S-phase and the 
accumulation of DSB damage, culminating in G2/M checkpoint 
activation. This indicates the Ru
II
 metal centre influences 
bioactivity and is not solely a “carrier” for the hydrophobic 
polypyridyl intercalating ligand. More detailed structural 
binding studies of Ru1 and dppz with DNA could be highly 
illuminating and provide a molecular basis for these 
observations. 
 
Ru1 generates metaphase chromosome non-attachment  
Close inspection revealed Ru1 induced chromosome 
misalignment in metaphase OE21 cells (Fig. 4a), possibly as a 
consequence of non-attachment of sister chromatids to 
spindle microtubules. To test this, Z-stack confocal analysis and 
3D reconstruction confirmed dispersion of condensed 
chromosomes in Ru1-treated populations with evidence of 
complete failure of attachment to the mitotic spindle (Figs 4b 
and S6†, Supplementary Videos 1 and 2). Misalignment was a 
consequence of failure of any kinetochore attachment as no 
monotelic, syntelic, or merotelic figures were observed. These 
mitotic aberrations accounted for ~8% of the total cell 
population at the IC50 concentration of Ru1 compared with 
1.2% for control cells (Fig. 4c). Examining the impact of Ru1 on 
m-phase progression, an increase in prophase, prometaphase 
and metaphase cells was observed with an accompanying 
decrease in anaphase, telophase and cytokinesis populations 
(Figs 4d,e). Increased levels of chromatin-associated activated 
(phosphorylated) p44/42 MAPK (mitogen-activated protein 
kinases) of aberrant metaphases indicated activation of the 
spindle assembly checkpoint (SAC) by Ru1 (Figs 4f and S7†) and 
confirming the absence of merotelic attachment as the latter 
do not activate the SAC.41-43 In addition, treatment with Ru1 
resulted in a large increase in cells containing multiple 
micronuclei (Figs 4g and S8†), indicaVng that despite acVvaVon 
of the SAC, a significant proportion of these cells fail to 
maintain SAC-induced mitotic arrest and progress through 
mitosis; such observations are a documented consequence of 
fragmented or detached chromosomes generated during 
mitosis.44 These results are therefore consistent with DNA 
damage accumulated during mitosis causing errors in 
chromosome segregation and spindle attachment failure, 
thereby resulting in SAC activation and delayed metaphase-to-
anaphase transition.
45
 This phenotype has been observed with 
other DNA-damaging agents, but these studies have always 
required genetic knockdown or co-treatment with a Chk1 
inhibitor to abrogate the G2 checkpoint to achieve this 
outcome.
46-48
 It is therefore significant that Ru1 generates this 
effect applied as a single-agent.  
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Fig. 4 (a) Misaligned metaphase chromosomes (yellow arrows) in OE21 cells treated 
with Ru1 (20 μM, 4 h). After fixation, cells were stained for α-tubulin (green) and DNA 
(DAPI, blue). MLCT (metal to ligand charge-transfer) emission of Ru1 included. (b) 3D 
representation of Ru1-treated OE21 cells (20 μM, 24 h) prepared from z-stack images. 
Non-aligned chromosomes in labelled cells shown by yellow arrows. (c) Quantification 
of aberrant mitoses in Ru1-treated OE21 cells (24 h). Data average of two independent 
experiments +/- S.D., >200 cells were counted for each condition. (d) CLSM images of 
mitotic stages of OE21 cells. (e) Quantification of mitotic sub-populations in Ru1-
treated OE21 cells (20 μM, 24 h). Data are expressed as a percentage of total cell 
population. Data average of two independent experiments +/- S.D., >200 cells counted 
per experiment. (f) Localisation of phospho(p)-p44/p42 MAP kinase in metaphase OE21 
cells treated with Ru1 (20 µM, 24 h), as determined by immunofluorescence 
(AlexaFluor594, white). DNA staining (DAPI, blue) included for reference. (g) Formation 
of micronuclei (red arrows) in OE21 cells treated with Ru1 (20 μM, 24 h). Data average 
of two independent experiments +/- S.D. where >100 cells were counted for each 
condition. Scale bars = 10 µm. 
 
Ru1 demonstrates distinct cancer cell-selectivity  
The dual-mode mechanism of action of Ru1 implies that 
rapidly-proliferating cells with an elevated mitotic index 
and/or mutations of mitotic checkpoint genes (characteristics 
of many oesophageal cancers
49, 50
) would be more susceptible 
to treatment. Accordingly, a panel of p53-deficient 
oesophageal cancer cell lines defective in Aurora kinase 
function
49, 50
 were treated with Ru1 and relative potency 
assessed by MTT assay, which measures both cytotoxic and 
growth inhibitory (cytostatic) effects.
51
 Immortalised human 
small airway epithelial hSAEC1-KT cells, which are p53-
functional, have a slow growth rate and low mitotic index,
52
 
were used as a control. Comparable cellular and nuclear 
uptake of Ru1 in the three cancer cell lines was observed (Fig. 
S1†), however, derived half-inhibitory (IC50) concentrations 
indicated that the relative potency of Ru1 was greatest 
towards OE21 cells (Table 1 and Fig. S9†), which possess the 
highest mitoVc index and growth rate (Table S1†). Notably, 
Ru1 demonstrates a two-fold greater potency than cisplatin in 
OE21 cells after 72 h incubation (Table 1). Encouragingly, 
reduced activity of Ru1 towards normal hSAEC1-KT cells was 
observed. In contrast, cisplatin showed comparable activity 
towards the cancer cell lines and consistent apoptosis 
induction across all cell lines tested, including hSAEC1-KT cells 
(Table 1 and Fig. S4b†). Dppz showed consistent activity 
towards the three cancer cell lines (Table 1) while the 
topoisomerase inhibitor doxorubicin demonstrated a three-
fold reduction in potency towards OE21 cells compared to 
OE33 or FLO-1 cells a_er 72 h exposure (Table S2†). These 
results indicate the cell-selectivity profile demonstrated by 
Ru1 is not a general outcome for DNA-damaging agents. The 
observation that dppz demonstrated comparable or greater 
potency than Ru1 and substantially greater effects than 
[Ru(phen)2(dppz)]
2+ is particularly striking as several RPC PDT 
candidates containing dppz-derived ligands exert bioactivity by 
light-activated ligand dissociation and it is often assumed their 
activity is due to the metal centre coordinating to DNA.26, 27, 53, 
54 These results are therefore consistent with the hypothesis 
that “uncaged” ligands play a significant role in these cases.54   
 
Table 1. IC50 values (µM) of Ru1, dppz, cisplatin or [Ru(phen)2(dppz)]
2+ towards OE21 
oesophageal squamous cell carcinoma, OE33 and FLO-1 human oesophageal 
adenocarcinoma cancer and hSAEC1-KT normal human small airway epithelial cells.a  
 OE21 OE33 FLO1 hSAEC1-KT 
 24 h 72 h 24 h 72 h 24 h 72 h 24 h 72 h 
Ru1 
21 ± 
4.2 
2.9 ± 
1.5 
44.5 ± 
3.5 
27 ± 
2.8 
42 ± 8 
11.5 ± 
2.1 
78.5 ± 
1.3 
22 ± 2 
dppz 
6.5 ± 
2.1 
3.3 ± 
0.4 
6.6 ± 2 
5.7 ± 
0.9 
7.5 ± 
0.8 
1.9 ± 
1.1 
>10 >10 
cisplatin 
22.6 ± 
3.6 
6.3 ± 
0.6 
11 ± 
1.4 
3.25 ± 
1 
26.5 ± 
0.7 
4.7 ± 
0.7 
21.5 ± 
5 
15.8 ± 
2 
[Ru(phen
)2(dppz)]
2+ 
>100 >100 >100 >100 >100 
34.0 ± 
5.7 
N.D. N.D. 
a Determined by MTT assay (24 or 72 h constant exposure). Data mean of two 
independent experiments +/− S.D. N.D. = not done. 
 
Mutagenicity of Ru1 
DNA cross-linking agents such as cisplatin are often 
mutagenic.
55
 Although increased micronuclei formation 
indicates Ru1 induces genotoxic stress, this effect was most 
apparent in OE21 cells (Table S3†), a cell line highly suscepVble 
to genotoxic insult due to chromosomal instability and Aurora 
kinase B dysfunction.
49
 Employing the hypoxanthine 
phosphorybosyl transferase (HPRT) forward mutation assay in 
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V79 Chinese hamster cells we show that although Ru1 does 
increase mutation frequency above control, the rate is 
approximately two-fold lower than for cisplatin (Table 2).  
 
Table 2. Mutation frequency (M. F.) induced by treatment with Ru1 or cisplatin, as 
determined by HPRT-forward mutation assay in V79 Chinese hamster cells.a 
M.F.b Rel. M.F.c 
Control 6.3 ± 2.4 1.0 
Ru1 36.7 ± 7.3 5.8 
cisplatin 65.5 ± 11.3 10.4 
a Cells were treated with 2 µM of each complex for 24 h. b 6-TG resistant 
mutations per 1x105 viable cells. c Ratio of induced to spontaneous mutations.  
 
Ru1 radiosensitizes cancer cells via DNA damage enhancement 
Many DNA-targeting drugs are employed as clinical 
radiosensitizers, as they induce specific DNA lesions and/or 
target cell-cycle progression to achieve synergy with IR 
targeted to cancer cells.
1, 2
 To determine whether Ru1 
functions as a radiosensitizer, three oesophageal cancer cell 
lines were pre-treated with sub-IC50 concentrations of Ru1 (2 
µM) for 24 h before irradiation (0 – 8 Gy IR; 
137
Cs-γ-rays; dose 
rate = 0.81 Gy min
-1
) and relative cytotoxicity assessed by 
clonogenic survival. Figure 5a shows that Ru1 decreases the 
surviving fraction (S.F.) of all cell lines in combined treatment 
compared to radiation alone. Single-agent Ru1 at this low 
concentration had a negligible impact on clonogenic survival 
(S.F. values >0.87, Table S4†), thereby demonstraVng the 
synergistic combination of Ru1 with IR. Resultant dose 
modification factors (DMF) at surviving fractions of 0.1 were 
1.19 - 1.31 for Ru1: a comparable level of radiosensitization to 
treatment of the same cell lines with sub-cytotoxic doses of 
cisplatin (DMFs at 0.1 = 1.05-1.44). The concentration required 
for radiosensitization by Ru1 offers a significant improvement 
over previous work using the multi-intercalator 
[Ru(dppz)2(PIP)
2+
]
23
 and is similar to more cytotoxic Ru(arene)-
halide monocationic complexes, which - like cisplatin -  rely 
upon metal-centred reactivity and the formation of 
coordination bonds with DNA.
56
  
DNA replication inhibitors often act as radiosensitizers by 
enhancing IR-induced cytotoxic DSB damage.
57,58
 Accordingly, 
levels of the DSB marker γH2AX
59
 in cell cultures pre-treated 
with Ru1 before exposure to IR were examined. As shown in 
Figures 5b-c, OE21 cells treated with Ru1 before IR (2 Gy) 
demonstrated a marked increase in γH2AX foci compared to 
single-agent treatment groups. The large increase in γH2AX 
foci in concomitant Ru1 and IR treatment indicated a 
substantial increase in IR-induced DSB formation compared to 
either treatment in isolation. A large increase in γH2AX levels is 
sustained even at higher doses of IR (8 Gy) and Ru1 (10 or 20 
µM) (Fig. 5d), implying a large therapeutic window exists to 
combine the effects of Ru1 and IR.  
Compared to work employing RPCs as photosensitizers, where 
in situ singlet oxygen or cytotoxic species formation is required 
for phototoxicity,
25
 radiosensitization often requires a 
complimentary cellular mechanism of action to enhance the 
DNA-damaging effects of IR.
57,58
 Considering many small 
molecules that inhibit DNA replication such as gemcitabine and 
5FU (fluorouracil) are potent radiosensitizers,
58
  it seems likely 
that the DNA-targeting properties of Ru1 and subsequent 
impact upon replication fork progression play a significant role 
in its radiosensitizing effects. Furthermore, G2/M phase cells 
are documented to be the most sensitive to IR-induced DNA 
damage,
1, 2
 and so the G2 arrest and metaphase block 
generated in response to Ru1–induced DNA damage would 
also be predicted to increase radiosensitivity; a concept 
supported by the high levels of γH2AX visible in Ru1-treated 
metaphase cells exposed to IR (Fig. 5b). In addition to these 
effects, work employing cisplatin has also indicated DNA repair 
inhibition contributes to radiosenstization,
4
 and it will be 
interesting to measure DNA repair kinetics in Ru1-
radiosensitized cells. Finally, although this work has 
established DNA as the primary target of Ru1, the peripheral 
coordination site on the tpphz ligand may additionally chelate 
metal ions.
60, 61
 In agreement with this principle, the addition 
of ten-fold excess Zn
2+
 and Fe
2+
 ions to free or DNA-bound Ru1 
resulted in a clear decrease in MLCT emission of the complex 
(Fig S10). Moreover, this effect was reversed by the addition of 
the metal chelator EDTA (ethylenediaminetetraacetic acid) for 
Zn
2+
 binding but, interestingly, not Fe
2+
, thereby demonstrating 
a high affinity of Ru1 for ferrous iron. These observations raise 
the possibility that Ru1 functions as a metal ion chelator in 
addition to binding DNA. While the possibility of intracellular 
chelation impacting bioactivity cannot be discounted, this 
effect would not be predicted to interfere with intercalative 
DNA binding
60, 61
 and the rapid block of replication fork 
progression by Ru1 and DDR activation timeframe are 
consistent with results obtained using non-chelating DNA-
binding compounds such as [Ru(dppz)2(PIP)
2+
].
23, 62
 However, 
this may be of relevance to other effects caused by Ru1 as iron 
chelators have been indicated to demonstrate radiosensitizing 
properties.
63, 64
 Future work will explore these concepts. 
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Fig. 5 (a) Clonogenic survival of OE21, OE33 or FLO-1 cells pre-treated with Ru1 (2 µM, 24 h) before irradiation with 0–8 Gy 137Cs-γ-rays. Mean +/− SEM of two or three independent 
experiments. Data were fit to a second order polynomial function (R2 values > 0.99). Data for sub-cytotoxic doses of cisplatin (Cis) (500 nM OE21 and OE33, 300 nM FLO-1 cells) 
included (dashed lines). (b) CLSM images of OE21 cells treated with Ru1 (10 µM, 24 h), IR (2 Gy), or both, where IR was applied at the end of Ru1 treatment.  Samples were fixed 1 
h after irradiation. Immunofluorescence staining with anti-γH2AX antibody (white) provides visualisation of DSB damage. DNA (DAPI) staining included for reference. Scale bars = 
10 µm. (c) Quantification of γH2AX foci/nucleus for OE21 cells treated as in (b). Data mean of two independent experiments +/- S.D. (d) Immunoblotting (top) and corresponding 
densitometry (bottom) of γH2AX levels in OE21 cells treated with Ru1 (24 h) with or without 8 Gy IR after treatment. Whole-cell extracts were prepared 1 h after irradiation and 
γH2AX levels were measured relative to β-actin loading controls by densitometry. Data normalised to untreated cells and are the mean +/- S.D. of two independent experiments. 
Conclusions 
In summary, we present a detailed characterisation of the 
cellular response to [Ru(phen)2(tpphz)]
2+
 (Ru1) in p53-deficient 
oesophageal cancer cells, finding this ruthenium(II) metallo-
intercalator induces a potent replication block accompanied by 
replication stress and DSB damage repair pathway activation, 
without triggering apoptosis. To our knowledge, this is the first 
example of a substitutionally inert ruthenium(II) mono-
intercalator demonstrated to function as a replication 
inhibitor. In parallel to this, metaphase chromosome 
attachment is impaired by Ru1. This multi-mode mechanism of 
action results in growth inhibition of highly proliferative 
oesophageal cancer cells with elevated mitotic indices. Finally, 
efficient radiosensitization through synergistic DNA damage 
enhancement illustrates the efficacy of Ru1 in combination 
with IR, where the lower mutagenicity and reduced 
cytotoxicity of Ru1 compared to cisplatin would be predicted 
to be advantageous in its use alongside radiotherapy.   
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The ruthenium(II) metallo-intercalator [Ru(phen)2(tpphz)]
2+
 simultaneously inhibits DNA replication, 
blocks mitosis and enhances DNA-damaging ionising radiation in oesophageal cancer cells.  
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